| ESCALATing care? Eltrombopag in pediatric aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice. |
|
Blood Advances |
Aplastic Anemia |
| Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide |
|
Blood Advances |
Aplastic Anemia |
| Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Genetics of Progression From MDS to Secondary Leukemia |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Clinical decision‐making and treatment of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
